Document:

Amended and Restated Right of First Refusal and Co-Sale Agreement

 Exhibit 10.8 
 COSKATA, INC. 
 AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 
 AUGUST 3, 2011 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	Definitions	  	 	1	  
			
	 2.
	 	Agreement Among the Company, the Investors and the Founder	  	 	3	  
			
		 	2.1    Right of First Refusal	  	 	3	  
			
		 	2.2    Right of Co-Sale	  	 	4	  
			
		 	2.3    Effect of Failure to Comply	  	 	6	  
			
	 3.
	 	Exempt Transfers	  	 	7	  
			
		 	3.1    Exempted Transfers	  	 	7	  
			
		 	3.2    Prohibited Transferees	  	 	7	  
			
		 	3.3    Exempted Offerings	  	 	8	  
			
	 4.
	 	Legends	  	 	8	  
			
	 5.
	 	Lock-Up	  	 	9	  
			
		 	5.1    Agreement to Lock-Up	  	 	9	  
			
		 	5.2    Stop Transfer Instructions	  	 	9	  
			
	 6.
	 	Miscellaneous	  	 	9	  
			
		 	6.1    Term	  	 	9	  
			
		 	6.2    Stock Split	  	 	10	  
			
		 	6.3    Ownership	  	 	10	  
			
		 	6.4    Costs of Enforcement	  	 	10	  
			
		 	6.5    Notices	  	 	10	  
			
		 	6.6    Entire Agreement	  	 	10	  
			
		 	6.7    Delays or Omissions	  	 	11	  
			
		 	6.8    Amendment; Waiver and Termination	  	 	11	  
			
		 	6.9    Assignment of Rights	  	 	11	  

							
	 	 	 	  	Page	 
			
		 	6.10    Severability	  	 	12	  
			
		 	6.11    Governing Law	  	 	12	  
			
		 	6.12    Titles and Subtitles	  	 	13	  
			
		 	6.13    Counterparts	  	 	13	  
			
		 	6.14    Aggregation of Stock	  	 	13	  
			
		 	6.15    Additional Founder	  	 	13	  
			
		 	6.16    Specific Performance	  	 	14	  

 Schedule A Investors 
 Schedule B Founder 

  
 ii 

 AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

THIS AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “Agreement”) is made as
of the 3rd day of August, 2011, by and among Coskata,
Inc., a Delaware corporation (the “Company”), the Investors and the Founder identified herein. Capitalized terms used as defined terms herein and not otherwise defined shall have the meaning ascribed to such terms in
Section 1 below. 
 WHEREAS, the Company, the Founder and certain of the Investors who purchased shares of Series A
Convertible Preferred Stock under the Series A Preferred Stock Purchase Agreement (the “Series A Investors”), Series B Convertible Preferred Stock under the Series B Preferred Stock Purchase Agreement (the “Series B
Investors”), Series C Convertible Preferred Stock under the Series C Preferred Stock Purchase Agreement dated October 29, 2008 or the Series C Preferred Stock Purchase Agreement dated April 19, 2010 (the “Series C
Investors” and, together with the Series A Investors and Series B Investors, the “Prior Investors”) have previously entered into that certain Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of
April 19, 2010 (the “Prior Agreement”); 
 WHEREAS, the Founder is the beneficial owner of the number of
shares of Capital Stock, or of options to purchase Common Stock, as set forth on Schedule B hereto; 
 WHEREAS, the
Company and certain of the Investors (the “Series D Investors”) are parties to the Series D Preferred Stock Purchase Agreement of even date herewith, pursuant to which the Series D Investors have acquired and have agreed to
purchase, respectively, shares of the Preferred Stock (as defined herein); 
 WHEREAS, the Founder, the Prior Investors and the
Company desire to further induce the Series D Investors to purchase the Preferred Stock. 
 NOW, THEREFORE, in consideration of
the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Company, the Founder and the Investors agree as follows: 

1. Definitions. 

“Capital Stock” means (a) shares of Common Stock and Preferred Stock (whether now outstanding or hereafter issued
in any context), (b) shares of Common Stock issued or issuable upon conversion of Preferred Stock, and (c) shares of Common Stock issued or issuable upon exchange, exercise and/or conversion, as applicable, of stock options, warrants or
other convertible securities of the Company, in each case now owned or subsequently acquired by the Founder, any Investor, or their respective successors or permitted transferees or assigns. For purposes of the number of shares of Capital Stock held
by an Investor or the Founder (or any other calculation based thereon), all shares of Preferred Stock shall be deemed to have been converted into Common Stock at the then applicable conversion rates. 

 “Certificate of Incorporation” means the Company’s Certificate of
Incorporation, as amended, effective as of the date hereof, as further amended from time to time. 
 “Common
Stock” means shares of Common Stock of the Company, $0.001 par value per share. 
 “Company Notice”
means written notice from the Company notifying the selling Founder that the Company intends to exercise its Right of First Refusal as to some or all of the Transfer Stock with respect to any Proposed Founder Transfer. 

“Founder” means GPV Fund II LLC, any successor or assign, and any other persons or entities who become parties hereto as
a Founder pursuant to Section 6.15. 
 “Investor Notice” means written notice from an Investor
notifying the Company and the Founder that such Investor intends to exercise its Secondary Refusal Right as to a portion of the Transfer Stock with respect to any Proposed Founder Transfer. 

“Investors” means the persons named on Schedule A hereto, each person to whom the rights of an Investor are
assigned pursuant to Section 6.9 and “Investor” means any one of them, as the context may require. 

“Preferred Stock” means shares of the Company’s Series A Convertible Preferred Stock, Series B Convertible
Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, each with a par value of $0.01 per share. 
 “Pro Rata Portion” means, with respect to each Investor, the proportion that the Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held by such
Investor, bears to the total Common Stock of the Company held by all Investors (on an as-converted to Common Stock basis). 

“Proposed Founder Transfer” means any proposed assignment, sale, offer to sell, pledge, mortgage, hypothecation,
encumbrance, disposition of or any other like transfer or encumbering of any Transfer Stock (or any interest therein) proposed by the Founder. 
 “Proposed Transfer Notice” means written notice from the Founder setting forth the terms and conditions of a Proposed Founder Transfer. 

“Prospective Transferee” means any person to whom the Founder proposes to make a Proposed Founder Transfer. 

“Right of Co-Sale” means the right, but not an obligation, of an Investor to participate in a Proposed Founder Transfer
on the terms and conditions specified in the Proposed Transfer Notice. 
 “Right of First Refusal” means the
right, but not an obligation, of the Company, or its permitted transferees or assigns, to purchase some or all of the Transfer Stock with respect to a Proposed Founder Transfer, on the terms and conditions specified in the Proposed Transfer Notice.

  
 2 

 “Secondary Notice” means written notice from the Company notifying the
Investors and the Founder that the Company does not intend to exercise its Right of First Refusal as to all shares of Transfer Stock with respect to any Proposed Founder Transfer. 

“Secondary Refusal Right” means the right, but not an obligation, of each Investor to purchase up to its Pro Rata
Portion of any Transfer Stock not purchased pursuant to the Right of First Refusal, on the terms and conditions specified in the Proposed Transfer Notice. 
 “Transfer Stock” means shares of Capital Stock owned by the Founder. 
 “Undersubscription Notice” means written notice from an Investor notifying the Company and the selling Founder that such Investor intends to exercise its option to purchase all or any
portion of the Transfer Stock not purchased pursuant to the Right of First Refusal or the Secondary Refusal Right. 
 2. Agreement Among the
Company, the Investors and the Founder. 
 2.1 Right of First Refusal. 

(a) Grant. Subject to the terms of Section 3 below, the Founder hereby unconditionally and irrevocably grants to the
Company a Right of First Refusal to purchase all or any portion of Transfer Stock that the Founder may propose to transfer in a Proposed Founder Transfer, at the same price and on the same terms and conditions as those offered to the Prospective
Transferee. 
 (b) Notice. The Founder proposing to make a Proposed Founder Transfer must deliver a Proposed Transfer
Notice to the Company and each Investor not later than forty-five (45) days prior to the consummation of such Proposed Founder Transfer. Such Proposed Transfer Notice shall contain the material terms and conditions (including price and form of
consideration) of the Proposed Founder Transfer and the identity of the Prospective Transferee. To exercise its Right of First Refusal under this Section 2, the Company must deliver a Company Notice to the Founder within fifteen
(15) days after delivery of the Proposed Transfer Notice. 
 (c) Grant of Secondary Refusal Right to Investors.
Subject to the terms of Section 3 below, the Founder hereby unconditionally and irrevocably grants to the Investors a Secondary Refusal Right to purchase all or any portion of the Transfer Stock not purchased by the Company pursuant to
the Right of First Refusal, as provided in this Section 2.1(c). If the Company does not intend to exercise its Right of Refusal with respect to all Transfer Stock subject to a Proposed Founder Transfer, the Company must deliver a
Secondary Notice to the selling Founder and to each Investor to that effect no later than fifteen (15) days after the Founder delivers the Proposed Transfer Notice to the Company. To exercise its Secondary Refusal Right, an Investor must
deliver an Investor Notice to the Founder and the Company within ten (10) days after the Company’s deadline for its delivery of the Secondary Notice as provided in the preceding sentence. 

  
 3 

 (d) Undersubscription of Transfer Stock. If options to purchase have been exercised
by the Company and the Investors with respect to some but not all of the Transfer Stock by the end of the 10-day period specified in the last sentence of Section 2.1(c)) (the “Investor Notice Period”), then the Company
shall, immediately after the expiration of the Investor Notice Period, send written notice (the “Company Undersubscription Notice”) to those Investors who fully exercised their Secondary Refusal Right within the Investor Notice
Period (the “Exercising Investors”). Each Exercising Investor shall, subject to the provisions of this Section 2.1(d), have an additional option to purchase all or any part of the balance of any such remaining
unsubscribed shares of Transfer Stock on the terms and conditions set forth in the Proposed Transfer Notice. To exercise such option, an Exercising Investor must deliver an Undersubscription Notice to the selling Founder and the Company within ten
(10) days after the expiration of the Investor Notice Period. In the event there are two or more such Exercising Investors that choose to exercise the last-mentioned option for a total number of remaining shares in excess of the number
available, all of such remaining shares available for purchase under this Section 2.1(d) shall be allocated to such Exercising Investors based on such Exercising Investors’ Pro Rata Portion. If the options to purchase all of such
remaining shares are exercised by one or more of the Exercising Investors, the Company shall immediately notify all of the Exercising Investors and the selling Founder of that fact. 

(e) Consideration; Closing. If the consideration proposed to be paid for the Transfer Stock is in property, services or other
non-cash consideration, the fair market value of the consideration shall be as determined in good faith by the Company’s Board of Directors and as set forth in the Company Notice. If the Company or any Investor cannot for any reason pay for the
Transfer Stock in the same form of non-cash consideration, the Company or such Investor may pay the cash value equivalent thereof, as determined in good faith by the Board of Directors and as set forth in the Company Notice. The closing of the
purchase of Transfer Stock by the Company and the Investors shall take place, and all payments from the Company and the Investors shall have been delivered to the selling Founder, by the later of (i) the date specified in the Proposed Transfer
Notice as the intended date of the Proposed Founder Transfer and (ii) forty-five (45) days after delivery of the Proposed Transfer Notice. 
 2.2 Right of Co-Sale. 
 (a) Exercise of Right. If any Transfer Stock
subject to a Proposed Founder Transfer is not purchased pursuant to Section 2.1 above and thereafter is to be sold to a Prospective Transferee, each respective Investor may elect to exercise its Right of Co-Sale and participate to the
extent of its Pro Rata Portion in the Proposed Founder Transfer as set forth in Section 2.2(b) below and otherwise on the same terms and conditions specified in the Proposed Transfer Notice (provided that if an Investor wishes to sell
Preferred Stock, the price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on the conversion ratio of the Preferred Stock into Common Stock). Each Investor who desires to exercise its Right of Co-Sale must give the
selling Founder written notice to that effect within fifteen (15) days after the deadline for delivery of the Secondary Notice described above, and upon giving such notice such Investor shall be deemed to have effectively exercised the Right of
Co-Sale. 

  
 4 

 (b) Shares Includable. Each Investor who timely exercises such Investor’s Right
of Co-Sale by delivering the written notice provided for above in Section 2.2(a) may include in the Proposed Founder Transfer all or any part of such Investor’s Capital Stock equal to the product obtained by multiplying (i) the
aggregate number of shares of Transfer Stock subject to the Proposed Founder Transfer (excluding shares purchased by the Company or the Investors pursuant to the Right of First Refusal or the Secondary Refusal Right) by (ii) a fraction, the
numerator of which is the number of shares of Capital Stock owned by such Investor immediately before consummation of the Proposed Founder Transfer (excluding any shares that such Investor has agreed to purchase pursuant to the Secondary Refusal
Right) and the denominator of which is the total number of shares of Capital Stock owned, in the aggregate, by all Investors immediately prior to the consummation of the Proposed Founder Transfer (excluding any shares that all Investors have
collectively agreed to purchase pursuant to the Secondary Refusal Right) plus the number of shares of Transfer Stock held by the selling Founder at such time. To the extent one or more of the Investors exercise such right of participation in
accordance with the terms and conditions set forth herein, the number of shares of Transfer Stock that the selling Founder may sell in the Proposed Founder Transfer shall be correspondingly reduced. 

(c) Delivery of Certificates. Each Investor shall effect its participation in the Proposed Founder Transfer by delivering to the
transferring Founder, no later than fifteen (15) days after such Investor’s exercise of the Right of Co-Sale, one or more stock certificates, properly endorsed for transfer to the Prospective Transferee, representing: 

(i) the number of shares of Common Stock that such Investor elects to include in the Proposed Founder Transfer; or 

(ii) the number of shares of Preferred Stock that is at such time convertible into the number of shares of Common Stock that such
Investor elects to include in the Proposed Founder Transfer; provided, however, that if the Prospective Transferee objects to the delivery of convertible Preferred Stock in lieu of Common Stock, such Investor shall first convert the
Preferred Stock into Common Stock and deliver Common Stock as provided above. The Company agrees to make any such conversion concurrent with and contingent upon the actual transfer of such shares to the Prospective Transferee. 

(d) Purchase Agreement. The parties hereby agree that the terms and conditions of any sale pursuant to this
Section 2.2 will be memorialized in, and governed by, a written purchase and sale agreement with customary terms and provisions for a transaction evidencing a simple purchase and sale of capital stock and the parties further covenant and
agree to enter into such an agreement as a condition precedent to any sale or other transfer pursuant to this Section 2.2. No Investor shall be required to make any representations or warranties in connection with such Proposed Founder
Transfer other than customary representations and warranties regarding title to the transferred shares, lack of encumbrances on such transferred shares and similar customary representations, and no Investor shall be required to perform any services
for any person or entity or, except for customary covenants to transfer the subject shares at the closing of the Proposed Founder Transfer, agree to any covenants to take any action or refrain from taking any action in connection with such transfer.

  
 5 

 (e) Deliveries. Each stock certificate an Investor delivers to the selling Founder
pursuant to Section 2.2(c) above will be transferred to the Prospective Transferee against payment therefor in consummation of the sale of the Transfer Stock pursuant to the terms and conditions specified in the Proposed Transfer Notice
and the purchase and sale agreement, and the selling Founder shall concurrently therewith remit or direct payment to each Investor the portion of the sale proceeds to which such Investor is entitled by reason of its participation in such sale. If
any Prospective Transferee or Transferees refuse(s) to purchase securities subject to the Right of Co-Sale from any Investor exercising its Right of Co-Sale hereunder, no Founder may sell any Transfer Stock to such Prospective Transferee or
Transferees unless and until, simultaneously with such sale, such Founder purchases all securities subject to the Right of Co-Sale from such Investor on the same terms and conditions (including the proposed purchase price as appropriately adjusted
based on the conversion ratio of the Preferred Stock into Common Stock) as set forth in the Proposed Transfer Notice. 
 (f)
Additional Compliance. If any Proposed Founder Transfer is not consummated within forty-five (45) days after receipt of the Proposed Transfer Notice by the Company, the Founder proposing the Proposed Founder Transfer may not sell or
otherwise transfer any Transfer Stock unless they first comply in full with each provision of this Section 2. The exercise or election not to exercise any right by any Investor hereunder shall not adversely affect its right to
participate in any other sales of Transfer Stock subject to this Section 2.2. 
 2.3 Effect of Failure to
Comply. 
 (a) Transfer Void; Equitable Relief. Any Proposed Founder Transfer not made in compliance with the
requirements of this Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of this
Agreement would result in substantial harm to the other parties hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that any non-breaching party hereto shall be
entitled to seek protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers of Transfer Stock not made
in strict compliance with this Agreement). 
 (b) Violation of First Refusal Right. If the Founder becomes obligated to
sell any Transfer Stock to the Company or any Investor under this Agreement and fails to deliver such Transfer Stock in accordance with the terms of this Agreement, the Company and/or such Investor may, at its option, in addition to all other
remedies it may have, send to such Founder the purchase price for such Transfer Stock as is herein specified and transfer to the name of the Company or such Investor (or request that the Company effect such transfer in the name of an Investor) on
the Company’s books the certificate or certificates representing the Transfer Stock to be sold. 

  
 6 

 (c) Violation of Co-Sale Right. If the Founder purports to sell any Transfer Stock in
contravention of the Right of Co-Sale (a “Prohibited Transfer”), each Investor who desires to exercise its Right of Co-Sale under Section 2.2 may, in addition to such remedies as may be available by law, in equity or
hereunder, require the Founder to purchase from such Investor the type and number of shares of Capital Stock that such Investor would have been entitled to sell to the Prospective Transferee under Section 2.2 had the Prohibited Transfer
been effected pursuant to and in compliance with the terms of Section 2.2. The sale will be made on the same terms and subject to the same conditions as would have applied had the Founder not made the Prohibited Transfer, except that the
sale (including, without limitation, the delivery of the purchase price) must be made within ninety (90) days after the Investor learns of the Prohibited Transfer, as opposed to the timeframe proscribed in Section 2.2. The Founder
shall also reimburse each Investor for any and all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Investor’s rights
under Section 2.2. 
 3. Exempt Transfers. 
 3.1 Exempted Transfers. 
 Notwithstanding the foregoing or anything to the contrary herein,
the provisions of Sections 2.1 and 2.2 shall not apply: (a) to a repurchase of Transfer Stock from the Founder by the Company, provided such repurchase was approved by a majority of the Board of Directors, including at least a
majority of the directors designated by the holders of Preferred Stock, or (b) upon a transfer of Transfer Stock by the Founder to its members or from its members made for bona fide estate planning purposes, or any other person approved by
unanimous consent of the Board of Directors of the Company, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, the Founder or any such
family members; provided that in the case of clause (b) the Founder shall deliver prior written notice to the Investors of such transfer and such shares of Transfer Stock shall at all times remain subject to the terms and restrictions
set forth in this Agreement and such transferee shall, as a condition to such issuance, deliver a counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as a
Founder (but only with respect to the securities so transferred to the transferee), including the obligations of the Founder with respect to Proposed Founder Transfers of such Transfer Stock pursuant to Section 2; and provided,
further, in the case of any transfer pursuant to clause (b) above, that such transfer is made pursuant to a transaction in which there is no consideration actually paid for such transfer. 

3.2 Prohibited Transferees. 
 Notwithstanding the foregoing, no Founder shall transfer any Transfer Stock to (a) any entity which, in the determination of the Company’s Board of Directors, directly or indirectly competes
with the Company or (b) any customer, distributor or supplier of the Company, if the Company’s Board of Directors should determine that such transfer would result in such customer, distributor or supplier receiving information that would
place the Company at a competitive disadvantage with respect to such customer, distributor or supplier. 

  
 7 

 3.3 Exempted Offerings. 
 Notwithstanding the foregoing or anything to the contrary herein, the provisions of Section 2 shall not apply to the sale of any Transfer Stock (a) to the public in an offering pursuant
to an effective registration statement under the Securities Act of 1933, as amended (a “Public Offering”) or (b) pursuant to a Deemed Liquidation Event (as defined in section 2.3 of part B of Article Fourth of the Certificate
of Incorporation). 
 4. Legends. 
 Each certificate representing shares of Transfer Stock held by the Founder or issued to any permitted transferee in connection with a transfer permitted by Section 3.1 hereof shall be endorsed
with the following legends: 
 “THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER, THE CORPORATION AND CERTAIN OTHER HOLDERS OF STOCK OF THE CORPORATION.
COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION.” 
 “THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A 180 DAY MARKET STANDOFF RESTRICTION AS SET FORTH IN A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER, THE CORPORATION AND CERTAIN OTHER HOLDERS OF STOCK OF THE
CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION. AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE INITIAL PUBLIC OFFERING
OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES.” 
 The Founder agrees that the
Company may instruct its transfer agent to impose transfer restrictions on the shares represented by certificates bearing the legends referred to in this Section 4 above to enforce the provisions of this Agreement, and the Company agrees
to promptly do so. The legends shall be removed upon termination of this Agreement at the request of the holder; provided, however, that the second legend above shall not be removed until the end of the lock-up period specified in Section 5.1
below. 

  
 8 

 5. Lock-Up. 
 5.1 Agreement to Lock-Up. 
 The Founder hereby agrees that it will not, without the prior
written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Company’s initial Public Offering (the “IPO”) and ending on the date specified by the Company and the
managing underwriter (such period not to exceed l80 days) or, if required by such underwriter, such longer period of time as is necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings
release or announcement by the Company within eighteen (18) days prior to or after the date that is one hundred eighty (180) days after the effective date of the registration statement relating to such offering, but in any event not to
exceed two hundred ten (210) days following the effective date of the registration statement relating to such offering (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Capital Stock held immediately prior to the effectiveness of the registration statement for the IPO or
(b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of Capital Stock, whether any such transaction described in clause (a) or
(b) above is to be settled by delivery of Capital Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 5 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, and shall only be applicable to the Founder if all officers, directors and greater than one percent (1%) stockholders of the Company are subject to the same or similar restrictions. The underwriters in
connection with the IPO are intended third-party beneficiaries of this Section 5 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Founder further agrees to execute
such agreements as may be reasonably requested by the underwriters in the IPO that are consistent with this Section 5 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of
any or all of such agreements by the Company or the underwriters shall apply to each Founder subject to such agreements pro rata based on the number of shares subject to such agreements. 

5.2 Stop Transfer Instructions. 
 In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the shares of Capital Stock of each Founder (and transferees and assignees thereof) until the
end of such restricted period. 
 6. Miscellaneous. 
 6.1 Term. 
 This Agreement shall automatically terminate upon the earlier of
(a) immediately prior to the consummation of the Company’s IPO (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or an
SEC Rule 145 transaction) and (b) the consummation of a Deemed Liquidation Event (as defined in section 2.3 of Part B of Article Fourth of the Certificate of Incorporation), pursuant to which the Investors receive cash or freely tradeable
securities or equivalent rights. Section 5 hereof shall survive any termination of this Agreement. 

  
 9 

 6.2 Stock Split. 
 All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any stock dividend, split, combination or other recapitalization affecting the Capital Stock occurring
after the date of this Agreement. 
 6.3 Ownership. 
 The Founder represents and warrants that the Founder is the sole legal and beneficial owner of the shares of Transfer Stock subject to this Agreement and that no other person or entity has any interest in
such shares (other than a community property interest as to which the holder thereof has acknowledged and agreed in writing to the restrictions and obligations hereunder). 
 6.4 Costs of Enforcement. 
 If any party to this Agreement seeks to enforce its rights
under this Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable attorneys’ fees. 

6.5 Notices. 
 All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given and received: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic
mail or confirmed facsimile if sent during normal business hours of the recipient, and if after normal business hours, then on the next business day (subject to confirmation of receipt), (c) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their address as set forth on Schedule A or Schedule B hereof, as the case may be, or to such email address, facsimile number or address as subsequently modified by written
notice given in accordance with this Section 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Christopher L. Kaufman, Esq., Latham & Watkins LLP, 140 Scott Drive, Menlo
Park, CA 94025, email: christopher.kaufman@lw.com. If notice is given to GPV Fund II LLC, a copy (which shall not constitute notice) shall also be sent to Peter Finn, Esq., Rubin and Rudman LLP, 50 Rowes Wharf, Boston, MA 02110, email:
pfinn@rubinrudman.com. Notwithstanding the foregoing, notice may be given to a party by confirmed electronic transmission or confirmed facsimile if an email address or facsimile number, respectively, for such party is set forth on Schedule A
or Schedule B hereof. 
 6.6 Entire Agreement. 
 This Agreement (including the Exhibits and Schedules hereto) constitutes the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other
written or oral agreement relating to the subject matter hereof existing between the parties, including, without limitation, the Prior Agreement, are expressly canceled. Without limiting the forgoing, this Agreement supersedes the Prior Agreement in
its entirety, and all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect. 

  
 10 

 6.7 Delays or Omissions. 
 No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right,
power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of
any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this
Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in a writing executed by such party and shall be effective only to the extent specifically set forth in such writing. All remedies, either
under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.8 Amendment;
Waiver and Termination. 
 This Agreement may be amended, modified or terminated (other than pursuant to Section 6.1 above) and
the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company, (b) the Founder and (c) the holders of
two-thirds (2/3) of the Preferred Stock. Any amendment, modification, termination or waiver so effected shall be binding upon the Company, the Investors, the Founder and all of their respective successors and permitted assigns whether or not
such party, assignee or other stockholder entered into or approved such amendment, modification, termination or waiver. Notwithstanding the foregoing: (i) the consent of the Founder shall not be required for any amendment, modification,
termination or waiver if such amendment, modification, termination or waiver does not apply to the Founder; (ii) Schedule B hereto may be amended by the Company from time to time in accordance with Section 6.15 hereto to add
information regarding additional Founders without the consent of the other parties hereto; (iii) Schedule A hereto may be amended by the Company from time to time to reflect assignments described in Section 6.9(c) without the
consent of the other parties hereto; and (iv) any provision hereof may be waived in an executed writing by the waiving party on such party’s own behalf, without the consent of any other party. The Company shall give prompt written notice
of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination or waiver. Any amendment, termination or waiver effected in accordance with
this Section 6.8 shall be binding on each party hereto and all of such party’s successors and permitted assigns, whether or not any such party, successor or assignee entered into or approved such amendment, termination or waiver. No
waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

6.9 Assignment of Rights. 
 (a) The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 

  
 11 

 (b) Any successor or permitted assignee of the Founder, including any Prospective Transferee
who purchases shares of Transfer Stock in accordance with the terms hereof, shall deliver to the Company and the Investors, as a condition to any transfer or assignment, a counterpart signature page hereto pursuant to which such successor or
permitted assignee shall confirm their agreement to be subject to and bound by all of the provisions set forth in this Agreement that were applicable to the predecessor or assignor of such successor or permitted assignee. For the avoidance of doubt,
no Investor purchasing any Transfer Stock pursuant to Section 2.1 shall be deemed to be a Founder to any extent, including with respect to such Transfer Stock, but each other transferee (other than the Company) that receives Transfer
Stock from a Founder shall be deemed a Founder with respect to such Transfer Stock. 
 (c) An Investor may assign its rights
hereunder (but only with all related obligations) to a transferee of all or a portion of the Investor’s Capital Stock (i) that is an Affiliate (as defined below in Section 6.14), partner, member, limited partner, retired
partner, retired member or stockholder of such investor or (ii), if after such transfer, the transferee holds the lesser of (A) at least 1,000,000 shares of Capital Stock or (B) all of the shares of Capital Stock originally held by the
Investor; provided: (1) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Capital Stock with respect to which such rights are being transferred;
and (2) such transferee agrees in writing to be bound by and subject to the terms and conditions of this Agreement as an Investor. For purposes of determining the number of shares of Capital Stock held by any Investor or a transferee, the
holdings of a transferee that is an Affiliate, limited partner, retired partner, member, retired member or stockholder of an Investor, shall be aggregated together with those of the transferring Investor. 

(d) Except in connection with an assignment by the Company by operation of law to the acquirer of the Company, the rights and obligations
of the Company hereunder may not be assigned under any circumstances. 
 6.10 Severability. 

In case any one or more of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and such invalid, illegal and unenforceable provision shall be reformed and construed so that it will be valid, legal and enforceable to
the maximum extent permitted by law. 
 6.11 Governing Law. 
 This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be
governed by and construed in accordance with the internal laws of the State of California, without regard to its principles of conflicts of laws. 

  
 12 

 6.12 Titles and Subtitles. 
 The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.13 Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 6.14 Aggregation of Stock. 
 All shares of Capital Stock held or acquired by Affiliates of Investors shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and the exercise of
any such rights may be allocated among such affiliated persons or entities in such manner as such affiliates may determine in their discretion. For purposes hereof, an “Affiliate” of an Investor means any general or limited partner
(including without limitation any retired partner) of any Investor that is a partnership, any manager or member (including without limitation any retired member) of any Investor that is a limited liability company, or any person or entity that,
directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such specified Investor, including any general partner or limited partner (including without limitation any retired partner),
manager or member (including without limitation any retired member), officer or director of such specified Investor, and any venture capital or private equity fund or other person now or hereafter existing which is controlled by or under common
control with such specified Investor or one or more general partners or managers of such specified Investor, or which shares the same management or parent company with such specified Investor. For purposes of the foregoing, “control”,
“controlled by” and “under common control with” with respect to any entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether
through the ownership of voting securities, partnership interests or by contract or otherwise. 
 6.15 Additional
Founder. 
 In the event that after the date of this Agreement, the Company issues shares of Common Stock, or options or other rights to
purchase Common Stock or securities ultimately convertible into, exercisable for or exchangeable for Common Stock, to any employee or consultant, which shares or options would collectively constitute with respect to such employee or consultant
(taking into account all shares of Common Stock, options and other purchase rights and Company securities held by such employee or consultant in each case as converted, exchanged and/or exercised for Common Stock) one percent (1%) or more of
the Company’s then outstanding Capital Stock (treating for this purpose all shares of Common Stock issuable upon exchange, exercise of or conversion of outstanding options, warrants or convertible securities, as if exercised, exchanged and/or
converted), then, the Company shall, in the case of the issuance of shares of Common Stock, as a condition precedent to such issuance, or, in the case of the issuance of options or other rights to purchase Common Stock or securities
ultimately 

  
 13 

 
convertible into, exercisable for or exchangeable for Common Stock, as a condition precedent to such employee’s or consultant’s conversion, exercise or exchange of such securities, as
the case may be, cause such employee or consultant to execute a counterpart signature page hereto as a Founder, and such person shall thereby be bound by, and subject to, all the terms and provisions of this Agreement applicable to the Founder.

 6.16 Specific Performance. 
 In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and
obligations of the Company and the Founder hereunder and to such other injunction or other equitable relief as may be granted by a court of competent jurisdiction. 
 [Remainder of Page Intentionally Left Blank] 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Right of First
Refusal and Co-Sale Agreement as of the date first above written. 
  

			
	COMPANY:
	
	COSKATA, INC.
		
	 By:
	 	 /s/ William J. Roe

	 Name: William J. Roe

	 Title: President and Chief Executive Officer

 SIGNATURE PAGE TO AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	FOUNDERS:
	
	GPV FUND II LLC
		
	By:	 	 /s/ Andrew Pellman

	 Andrew Pellman, Manager
 Hereunto Duly Authorized

 SIGNATURE PAGE TO AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	FOUNDERS:
	
	 /s/ Todd Kimmel

	Todd Kimmel

 SIGNATURE PAGE TO AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	FOUNDERS:
	
	 /s/ William J. Roe

	William J. Roe

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	FOUNDERS:
	
	 /s/ David Blair

	David Blair

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	FOUNDERS:
	
	 /s/ Richard Tobey

	Richard Tobey

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	FOUNDERS:
	
	 /s/ Jeffrey Burgard

	Jeffrey Burgard

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	Blackstone Tenex L.P.
	Blackstone Clean Technology Partners, L.P.
	Blackstone Family Cleantech Investment
	Partnership, L.P.
	Blackstone Family Cleantech Investment
	Partnership SMD, L.P.
	
	By: Blackstone Cleantech Venture Associates
	L.L.C., its general partner
		
	By:	 	 /s/ Jamie Kiggen

	Name: Jamie Kiggen
	Title: Authorized Person

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	TOTAL ENERGY VENTURES
	INTERNATIONAL, S.A.S.
		
	By:	 	 /s/ Manoelle Lepoutre

	Name: Manoelle Lepoutre
	Title: President

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	CCM QUALIFIED MASTER FUND, LTD.
		
	By:	 	 /s/ Clint D. Coghill

	Name:	 	Clint D. Coghill
	Title:	 	Director
	
	CCM SPV II, LLC
		
	By:	 	 /s/ Clint D. Coghill

	Name:	 	Clint D. Coghill
	Title:	 	President and CIO of Managing
		 	Member, Coghill Capital Management, LLC

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	 ADVANCED TECHNOLOGY VENTURES
 VII, L.P.

		
	By:	 	ATV Associates VII, LLC, its General Partner
		
	By:	 	 /s/ William Wiberg

	Name:	 	William Wiberg
	Title:	 	Managing Director
	
	 ADVANCED TECHNOLOGY VENTURES
 VII (B), L.P.

		
	By:	 	ATV Associates VII, LLC, its General Partner
		
	By:	 	 /s/ William Wiberg

	Name:	 	William Wiberg
	Title:	 	Managing Director
	
	 ADVANCED TECHNOLOGY VENTURES
 VII (C), L.P.

		
	By:	 	ATV Associates VII, LLC, its General Partner
		
	By:	 	 /s/ William Wiberg

	Name:	 	William Wiberg
	Title:	 	Managing Director
	
	ATV ENTREPRENEURS VII, LP
		
	By:	 	ATV Associates VII, LLC, its General Partner
		
	By:	 	 /s/ William Wiberg

	Name:	 	William Wiberg
	Title:	 	Managing Director

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	KHOSLA VENTURES II, LP
		
	 By:
	 	     Khosla Ventures Associates II, LLC, a
     Delaware limited liability company and
     general
partner of Khosla Ventures II, LP

		
	 By:
	 	 /s/ Samir Kaul

	 Name: Samir Kaul

	 Title: Member

	
	 KHOSLA VENTURES III, LP

		
	 By:
	 	     Khosla Ventures Associates III, LLC, a
     Delaware limited liability company and
     general
partner of Khosla Ventures III, LP

		
	 By:
	 	 /s/ Samir Kaul

	 Name: Samir Kaul

	 Title: Member

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

			
	INVESTORS:
	
	GENERAL MOTORS VENTURES LLC
		
	By:	 	 /s/ Jon Lauckner

			
	Name: Jon Lauckner
	Title: President

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	GLOBESPAN CAPITAL PARTNERS V, L.P.
		
	By:	 	Globespan Management Associates V, L.P.
		 	  Its sole General Partner
		
	By:	 	Globespan Management Associates V, LLC
		 	  Its sole General Partner
		
	By:	 	 /s/ Andrew P. Goldfarb

	Name: Andrew P. Goldfarb
	Title: Member

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	TRIPLEPOINT CAPITAL LLC
		
	By:	 	 /s/ Sajal Srivastava

	Name: Sajal Srivastava
	Title: Chief Operating Officer

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	THE LYNCH FOUNDATION u/a 07/14/88
		
	By:	 	 /s/ Peter S. Lynch

	Name: Peter S. Lynch
	Title: Trustee
	
	PETER AND CAROLYN LYNCH JT TEN WROS
		
	By:	 	 /s/ [illegible]

	Name:
	Title:
	
	LYNCH CHILDRENS TRUST fbo ANNE LYNCH u/a 03/08/88
		
	By:	 	 /s/ Carolyn A. Lynch

	Name: Carolyn A. Lynch
	Title: Trustee
	
	LYNCH CHILDRENS TRUST fbo ELIZABETH LYNCH u/a 03/08/88
		
	By:	 	 /s/ Carolyn A. Lynch

	Name: Carolyn A. Lynch
	Title: Trustee
	
	LYNCH CHILDRENS TRUST fbo MARY LYNCH u/a 03/08/88
		
	By:	 	 /s/ Carolyn A. Lynch

	Name: Carolyn A. Lynch
	Title: Trustee

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	PETER S. LYNCH CHARITABLE LEAD ANNUITY u/a 03/27/96
		
	By: 	 	 /s/ Carolyn A. Lynch

			
	Name:	 	Carolyn A. Lynch
	Title:	 	Trustee
	
	PETER S. LYNCH CHARITABLE LEAD UNITRUST u/a 03/03/97

 
			
		
	By: 	 	 /s/ Carolyn A. Lynch

			
	Name:	 	Carolyn A. Lynch
	Title:	 	Trustee
	
	PETER S. AND CAROLYN A. LYNCH 1999 UNITRUST u/a 12/28/99

 
			
		
	By: 	 	 /s/ Peter S. Lynch

			
	Name:	 	Peter S. Lynch
	Title:	 	Trustee

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	WEISS FAMILY TRUST
		
	By:  	 	 /s/ [illegible]

	Name:
	Title:

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	INVESTORS:
	
	ROGER KIMMEL
	
	 /s/ Roger Kimmel

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	MEGAN WEISS AND ERIC NEEDLEMAN
		
	By: 	 	 /s/ [illegible]

	Name:
	Title:

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	INVESTORS:
	
	MELISSA KIMMEL
	
	 /s/ Melissa Kimmel

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	 SC GREEN ENERGY TECH, INC. 
 (a Sumitomo Corporation green energy tech investment company)

		
	By:	 	 /s/ Tsuyoshi Kondo

	Name: Tsuyoshi Kondo
	Title: President
	
	PRESIDIO VENTURES, INC.
		
	By:	 	 /s/ Toshihiko Kusakabe

	Name: Toshihiko Kusakabe
	Title: CEO & President

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	ARANCIA INTERNATIONAL INC.
		
	By:	 	 /s/ Ignacio Aranguren

			
	Name:	 	Ignacio Aranguren
	Title:	 	President

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
	
	INVESTORS:
	
	WILLIAM J. ROE
	
	 /s/ William J. Roe

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 
			
	INVESTORS:
	
	 REVOCABLE TRUST OF BRADLEY J.
 BELL DATED DECEMBER 21, 1988 AS AMENDED AND RESTATED

		
	By:	 	 /s/ Bradley J. Bell

			
	Name: Bradley J. Bell
	Title: Authorized Signatory

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 SCHEDULE A 

INVESTORS 
  

																	
	 Name and Address
	  	Number of Shares
of Series A
Preferred Stock	 	  	Number of Shares
of 
Series B
Preferred Stock	 	  	Number of Shares
of Series
C
Preferred Stock	 	  	Number of Shares
of 
Series D
Preferred Stock	 
	 The Blackstone Investors:
	  				  				  				  			
	 Blackstone Tenex L.P.

c/o The Blackstone Group

345 Park Avenue
 New York, NY 10154
 Attn: Jamie Kiggen, Senior
Managing
 Director
	  	 	0	  	  	 	0	  	  	 	4,166,666	  	  	 	0	  
	 Blackstone Clean Technology

Partners, L.P.
 c/o The Blackstone Group
 345 Park Avenue

New York, NY 10154

Attn: Jamie Kiggen, Senior Managing

Director
	  	 	0	  	  	 	0	  	  	 	1,601,251	  	  	 	0	  
	 Blackstone Family Cleantech

Investment Partnership, L.P.

c/o The Blackstone Group

345 Park Avenue
 New York, NY 10154
 Attn: Jamie Kiggen, Senior
Managing
 Director
	  	 	0	  	  	 	0	  	  	 	16,993	  	  	 	1,000,000	  
	 Blackstone Family Cleantech

Investment Partnership SMD, L.P.

c/o The Blackstone Group

345 Park Avenue
 New York, NY 10154
 Attn: Jamie Kiggen, Senior
Managing
 Director
	  	 	0	  	  	 	0	  	  	 	160,923	  	  	 	0	  
	 Total Energy Ventures International, S.A.S.
	  	 	0	  	  	 	0	  	  	 	1,666,667	  	  	 	257,143	  
	 Tour Coupole , 2 Place Jean Millier

La Defense 6, 92400

Courbevoie, France
	  				  				  				  			
	 CCM Qualified Master Fund, Ltd.
	  	 	0	  	  	 	517,384	  	  	 	0	  	  	 	0	  
	 CCM SPV II, LLC 
	  	 	0	  	  	 	432,338	  	  	 	0	  	  	 	0	  
	 One North Wacker Drive, Suite 4350

Chicago, IL 60606
	  				  				  				  			
	 General Motors Ventures LLC
	  	 	0	  	  	 	949,722	  	  	 	0	  	  	 	90,914	  
	 Mail Code 482-C37-D99

300 Renaissance Center

Detroit, MI 48265

Attn: Tim Brumbaugh
	  				  				  				  			

																	
	 Name and Address
	  	Number of Shares
of Series
A
Preferred Stock	 	  	Number of Shares
of 
Series B
Preferred Stock	 	  	Number of Shares
of Series
C
Preferred Stock	 	  	Number of Shares
of Series D
Preferred Stock	 
	 The Advanced Technology Investors:
	  				  				  				  			
	 Advanced Technology Ventures VII, L.P.
 Bay Colony Corporate Center
 1000 Winter Street, Suite 3700

Waltham, MA 02451-1148
	  	 	3,416,627	  	  	 	713,153	  	  	 	1,066,914	  	  	 	497,465	  
	 Advanced Technology Ventures VII

(B), L.P.
 Bay Colony Corporate Center
 1000 Winter Street, Suite
3700
 Waltham, MA 02451-1148
	  	 	137,108	  	  	 	28,619	  	  	 	42,814	  	  	 	19,963	  
	 Advanced Technology Ventures VII

(C), L.P.
 Bay Colony Corporate Center
 1000 Winter Street, Suite
3700
 Waltham, MA 02451-1148
	  	 	65,903	  	  	 	13,756	  	  	 	20,579	  	  	 	9,595	  
	 ATV Entrepreneurs VII, L.P.

Bay Colony Corporate Center

1000 Winter Street, Suite 3700

Waltham, MA 02451-1148
	  	 	20,362	  	  	 	4,251	  	  	 	6,358	  	  	 	2,965	  
	 Khosla Ventures II, LP
	  	 	6,360,000	  	  	 	284,917	  	  	 	0	  	  	 	0	  
	 3000 Sand Hill Road, Bldg. 3, Suite 170

Menlo Park, CA 94025

Attn: Kim Totah
	  				  				  				  			
	 Khosla Ventures III, LP
	  	 	0	  	  	 	0	  	  	 	2,030,001	  	  	 	830,425	  
	 3000 Sand Hill Road, Bldg. 3, Suite 170

Menlo Park, CA 94025

Attn: Kim Totah
	  				  				  				  			
	 Globespan Capital Partners V, L.P.
	  	 	0	  	  	 	569,833	  	  	 	250,001	  	  	 	78,480	  
	 300 Hamilton Avenue

Palo Alto, CA 94301
	  				  				  				  			
	 TriplePoint Capital
	  	 	0	  	  	 	94,972	  	  	 	50,000	  	  	 	0	  
	 2755 Sand Hill Rd

Menlo Park, CA 94025
	  				  				  				  			
	 The Lynch Entities Investors:
	  				  				  				  			
	 The Lynch Foundation u/a 07/14/88

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Peter S. Lynch, Trustee
	  	 	0	  	  	 	44,637	  	  	 	0	  	  	 	7,143	  
	 Peter and Carolyn Lynch JT Ten

WROS
 82 Devonshire Street, S4A
 Boston, MA
02109
	  	 	0	  	  	 	30,391	  	  	 	0	  	  	 	7,143	  

																	
	 Name and Address
	  	Number of Shares
of Series
A
Preferred Stock	 	  	Number of Shares
of 
Series B
Preferred Stock	 	  	Number of Shares
of Series
C
Preferred Stock	 	  	Number of Shares
of Series D
Preferred Stock	 
	 Lynch Childrens Trust fbo Anne

Lynch u/a 03/08/88

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Carolyn A. Lynch, Trustee
	  	 	0	  	  	 	4,939	  	  	 	0	  	  	 	473	  
	 Lynch Childrens Trust fbo Elizabeth

Lynch u/a 03/08/88

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Carolyn A. Lynch, Trustee
	  	 	0	  	  	 	4,939	  	  	 	0	  	  	 	473	  
	 Lynch Childrens Trust fbo Mary

Lunch u/a 03/08/88

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Carolyn A. Lynch, Trustee
	  	 	0	  	  	 	4,939	  	  	 	0	  	  	 	473	  
	 Peter S. Lynch Charitable Lead

Annuity u/a 03/27/96

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Carolyn A. Lynch, Trustee
	  	 	0	  	  	 	6,078	  	  	 	0	  	  	 	7,143	  
	 Peter S. Lynch Charitable Lead

Unitrust u/a 03/03/97

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Carolyn A. Lynch, Trustee
	  	 	0	  	  	 	6,648	  	  	 	0	  	  	 	636	  
	 Peter S. and Carolyn A. Lynch 1999

Unitrust u/a 12/28/99

82 Devonshire Street, S4A

Boston, MA 02109
 Attn: Peter S. Lynch, Trustee
	  	 	0	  	  	 	39,888	  	  	 	0	  	  	 	3,818	  
	 Weiss Family Trust
	  	 	0	  	  	 	18,994	  	  	 	0	  	  	 	11,006	  
	 100 Irvine Cove Place

Laguna Beach, CA 92651

Attn: Dr. Stephen and Renee Weiss
	  				  				  				  			
	 Roger Kimmel
	  	 	0	  	  	 	18,994	  	  	 	0	  	  	 	11,006	  
	 1046 Lake Avenue

Greenwich, CT 06831
	  				  				  				  			
	 Megan Weiss and Eric Needleman
	  	 	0	  	  	 	4,748	  	  	 	0	  	  	 	455	  
	 1471 North Doheny Drive

Los Angeles, CA 90069
	  				  				  				  			
	 Melissa Kimmel
	  	 	0	  	  	 	4,748	  	  	 	0	  	  	 	455	  
	 7012 Arandale Road

Bethesda, MD 20817
	  				  				  				  			

																	
	 Name and Address
	 	Number of Shares
of Series
A
Preferred Stock	 	 	Number of Shares
of 
Series B
Preferred Stock	 	 	Number of Shares
of Series
C
Preferred Stock	 	 	Number of Shares
of Series D
Preferred Stock	 
	 SC Green Energy Tech, Inc.
 Attn: Hajime Uchiike
 600 Third Avenue

New York, NY 10016
	 	 	0	  	 	 	0	  	 	 	166,667	  	 	 	0	  
	 Presidio Ventures, Inc.

Attn: Hajime Uchiike

600 Third Avenue
 New York, NY 10016
	 	 	0	  	 	 	0	  	 	 	0	  	 	 	15,955	  
	 William J. Roe

c/o Coskata, Inc.

4575 Weaver Parkway, Suite 100

Warrenville, IL 60555
	 	 	0	  	 	 	0	  	 	 	66,667	  	 	 	6,382	  
	 Arancia International Inc.

c/o One Wilshire Boulevard., Ste 2000

Los Angeles, CA 90017-3321

Attn: S. L. Bradford
	 	 	0	  	 	 	0	  	 	 	208,334	  	 	 	19,943	  
	 Revocable Trust of Bradley J. Bell dated

December 21, 1988 as amended and restated
 28 Muirfield
 Wheaton, IL 60189
	 	 	0	  	 	 	0	  	 	 	50,000	  	 	 	4,786	  

 SCHEDULE B 

FOUNDERS 
  

					
	 Name
	  	Number of Shares of
Capital Stock	 
	 GPV FUND II LLC
	  	 	5,363,636	  
	 TODD B. KIMMEL
	  	 	454,750	  
	 WILLIAM J. ROE
	  	 	*	  
	 DAVID BLAIR
	  	 	*	  
	 RICHARD TOBEY
	  	 	*	  
	 JEFFREY BURGARD
	  	 	*	  
	 Total:
	  	 	5,818,386	  
		  	  
	  
	 

  

	*	Options to purchase common stock constituting 1% or more of the Company’s outstanding capital stock.Offer Letter, dated September 4, 2007, between Coskata, Inc. and William J. Roe

 Exhibit 10.9 
 

 
 September 4, 2007 
 William J. Roe 
 611 Nanak Court 

Naperville, Illinois 60565 
 Dear Bill, 
 On behalf of Coskata (the “Company”), I am very excited to
offer you the position of President and Chief Executive Officer. Speaking for the Company’s Board of Directors (the “Board”), and the Company’s management team, we are all very impressed with you and what you will bring to the
Company. We believe that with your background and personal ambitions to build a great company, you will make significant contributions to the success of Coskata. 
 The terms of your new position with the Company are as set forth below: 
 1. On or before
September 15, 2007, you will become the President, Chief Executive Officer and Director of the Company. As CEO you will have responsibility for the Company’s operations and strategic direction, as well as other tasks assigned to you by the
Board. You will report directly to the Board. While employed by the Company, except with the written approval of the Board, you will not actively engage in any other employment, occupation or consulting activity. 

2. Start Date. You will commence this new position with the Company on or before September 15, 2007. It is understood that you will have 10
days off in October, 2007. 
 3. Compensation. 
 a. Base Salary. You will be paid a monthly salary of $22,916.66 minus applicable withholdings, which is equivalent to $275,000 on an annualized basis. Your salary will be payable pursuant to the
Company’s regular payroll policy (or in the same manner as other officers of the Company). 
 b. Bonus Program. The Board would like to
work with you to create a mutually agreeable bonus program for yourself and other members of the management team of the Company that will allow you and the team to participate in upside success of the Company’s performance. Your targeted annual
bonus will be $75,000 based on milestones set forth by the Board of Directors. This bonus is payable by the end of CY 2008. The Board will discuss with you the creation of this program within your first 90 days of employment. 

4. Stock Options. 
 a. Initial Grant. In
connection with the commencement of your employment, the Company will grant you an option to purchase 1,080,000 shares of Restricted Stock, with an exercise price equal to the fair market value of the Restricted Stock of the Company on the date of
the grant. The proposed award represents approximately 6.0% of the fully diluted outstanding capitalization of the Company. The option will vest and become exercisable, contingent on your continued employment with the Company on each respective
vesting date, over a period of 5 years as follows: one year after your start date, 20% of the option will vest; thereafter, the remaining shares will vest on a monthly schedule of 1/48 of the total number of shares subject to

 
the grant upon the completion of each month of employment. The option will be an incentive stock option to the maximum extent allowed by the tax code and will be subject to the terms of the
Company’s Stock Option Plan and the Stock Option Agreement between you and the Company, which you will be required to execute as a condition of the grant. 
 5. Benefits. 
 a. Insurance Benefits. The Company will provide you with the standard medical
and dental insurance benefits available to other employees of the Company. 
 b. Vacation. It is understood that you will be eligible for up to
five (5) weeks of vacation per year. 
 6. At-Will Employment. Your employment with the Company shall be for no specified period or
term and may be terminated by you or by the Company at any time for any or no reason, with or without Cause, as long as written notice is provided the Company that you provide thirty (30) days written notice of your intention to resign. The
“at-will” nature of your employment shall remain unchanged during your tenure as an employee of the Company, and may only be changed by an express written agreement that is signed by you and by the Chairman of the Board. 

For all purposes under this Agreement, a termination for “Cause” shall mean a determination by the Board that your employment be terminated for
any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Company; (ii) a violation of a federal or state law or regulation applicable to the business of the
Company; (iii) conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misappropriation of property belonging to the Company or its affiliates; (v) non-performance, non-compliance
or interference with the other party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer, (vi) your failure to satisfactorily perform your
duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties. 

7. Change of Control. If, during your employment with the Company, there is a Change of Control event, and the Company terminates your employment
without Cause or you are Constructively Terminated within 6 months of that event, then you will be eligible for immediate accelerated vesting of 50% of any of the unvested shares under your outstanding options as of the date of termination.

 “Change of Control” shall be defined as (i) merger, reorganization, consolidation or other acquisition (or series of related
transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all equity of the Company would be transferred by the holders of the Company’s outstanding shares (excluding a reincorporation to effect a
change in domicile); (ii) a sale of all or substantially all of the assets of the Company; or (iii) any other transaction or series of transactions, in which the Company’s stockholders immediately prior to such transaction or
transactions own immediately after such transaction less than 50% of the voting equity securities of the surviving corporation or its parent . 

8. Confidential Information and Invention Assignment Agreement. As an employee of the Company, you will have access to certain Company
confidential information and you may during the course of your employment develop certain information or inventions, which will be the property of the Company. To protect the interest of the Company you will need to sign the Company’s standard
“Employee Confidentiality Agreement” as a condition of your employment, a copy of which is enclosed. 

  
 2 

 9. No Inconsistent Obligations. By accepting this offer of employment, you represent and warrant to
the Company that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this letter. You also represent and warrant that you will not use or disclose, in connection
with your employment by the Company, any trade secrets or other proprietary information or intellectual property in which you or any other person has any right, title or interest, and that your employment by the Company will not infringe upon or
violate the rights of any other person or entity. You represent and warrant to the Company that you have returned all property and confidential information relating to any prior employers. 
 We are all delighted to be able to extend this offer and look forward to working with you. To indicate your acceptance of the Company’s offer, please sign and date this letter the space provided
below, and also sign the enclosed Employee Confidentiality Agreement, and return both to me. A duplicate original is enclosed for your records. This letter agreement, together with the Employee Confidentiality Agreement and any stock option and
purchase agreements, sets forth our entire agreement and understanding regarding the terms of your employment with Company and supersedes any prior representations or agreements, whether written or oral (including that certain offer letter also
dated as of the date hereof). This letter agreement may not be modified or amended except by a written agreement, signed by the Chairman of the Board of the Company and by you. 
 This offer, if not accepted, will expire at close of business on Wednesday, September 5, 2007. 
 Sincerely, 
 On Behalf of the Board of Directors 

 

					
	/s/ Samir Kaul	 		 	/s/ Bill Wiberg
	Samir Kaul, Khosla Ventures	 		 	Bill Wiberg, Advanced Technology Ventures

  

	
	/s/ Aaron Mandell
	Aaron Mandell, Great Point Ventures

 Agreed and Accepted September 17, 2007 
  

	
	/s/ William J. Roe
	William J. Roe

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]